Patents by Inventor Suobao Rong

Suobao Rong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KAT II inhibitors
    Patent number: 8933095
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: January 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Amy Beth Dounay, Laura Ann McAllister, Vinod Dipak Parikh, Suobao Rong, Patrick Robert Verhoest
  • KAT ll INHIBITORS
    Publication number: 20140057938
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: Pfizer Inc.
    Inventors: AMY BETH DOUNAY, LAURA ANN MCALLISTER, VINOD DIPAK PARIKH, SUOBAO RONG, PATRICK ROBERT VERHOEST
  • KAT II inhibitors
    Patent number: 8598200
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 3, 2013
    Assignee: Pfizer Inc.
    Inventors: Amy B Dounay, Laura McAllister, Vinod D Parikh, Suobao Rong, Patrick R Verhoest
  • KAT ll INHIBITORS
    Publication number: 20120302599
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Application
    Filed: November 30, 2011
    Publication date: November 29, 2012
    Inventors: Amy B. Dounay, Laura McAllister, Vinod D. Parikh, Suobao Rong, Patrick R. Verhoest
  • Bicyclic and tricyclic compounds as KAT II inhibitors
    Patent number: 8183238
    Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: May 22, 2012
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan
  • Bicyclic And Tricyclic Compounds As KAT II Inhibitors
    Publication number: 20100324043
    Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan